HEM.V - Hemostemix Inc.
| Previous Close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0050 x 0 |
| Ask | 0.0100 x 0 |
| Day's Range | 0.0100 - 0.0100 |
| 52 Week Range | 0.0050 - 0.0500 |
| Volume | 10,500 |
| Avg. Volume | 1,828,788 |
| Market Cap | 7.302M |
| Beta (5Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Delaware Court Grants An Order for the Expedited Briefing Schedule of Hemostemix's Injunction against Accudata Solutions, Inc. and Hemostemix is in Receipt of an Unsigned Report from Aspire Health Science
Calgary, Alberta--(Newsfile Corp. - July 6, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that the United States District Court for the District of Delaware has granted an order for the expedited briefing schedule on Hemostemix's Injunction application seeking the immediate return of all clinical trial data from Accudata Solutions, Inc. ("Accudata"). The Order directs Defendant Accudata to file an Answering Brief in response to Hemostemix's ...
- Newsfile
Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data
Calgary, Alberta--(Newsfile Corp. - July 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce on June 29, 2020, it filed a Verified Complaint and, on July 2, 2020, Motions for a Preliminary Injunction and Expedited Scheduling seeking to compel the immediate return of all clinical trial data from Defendant Accudata Solutions, Inc. ("Accudata") and enjoining Accudata from continuing to divulge and disclose such highly sensitive and ...
- Newsfile
Hemostemix Appeals Alberta Court's Service Ex Juris Decision
Calgary, Alberta--(Newsfile Corp. - June 24, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that, further to its June 19, 2020 news release, Hemostemix has filed a fast track appeal in relation to the Alberta Court of Queen's Bench erroneous service ex juris decision rendered on June 18, 2020 in relation to Hemostemix's Replevin application seeking access to and a copy of Hemostemix's own property which is being wrongfully ...
- Newsfile
Hemostemix Announces $700,000 Non Broker Private Placement, Update on its Proceedings against Aspire Health Science, LLC
Calgary, Alberta--(Newsfile Corp. - June 19, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement of units ("Units") for gross proceeds of up to $700,000 (the "Offering"), subject to TSX Venture Exchange (the "Exchange") approval. The Offering may consist of the issuance of an aggregate of 70,000,000 Units at a price of $0.01 per Unit. Each Unit consists of one Common Share in ...
- Newsfile
Hemostemix Announces Delay in Filing of Annual Financial Statements and Application for Management Cease Trade Order
Calgary, Alberta--(Newsfile Corp. - June 16, 2020) - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV: HEM) (OTC: HMTXF) announces, that it has not met the revised filing date, as provided in Alberta Blanket Order 51-517 Temporary Exemption from Certain Corporate Finance Requirements (the "Alberta Order") of the Alberta Securities Commission (and similar exemptions provided by the securities commission in British Columbia) of June 15, 2020, for filing of the following continuous disclosure documents (collectively, ...
- Newsfile
Hemostemix Announces Aspire Health Science, LLC Has No Right to Manufacture or to Sublicense Hemostemix's Intellectual Property
Calgary, Alberta--(Newsfile Corp. - June 8, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that ownership and control of its intellectual property is an uncontested fact, and the Company is in communication with each clinical trial site. The Company has lawfully and properly cancelled certain license rights to Aspire Health Science, LLC ("Aspire")."Hemostemix's intellectual property is uncontested," said Thomas Smeenk, CEO. "We reserve our rights ...
- Newsfile
Hemostemix Announces Dr. Mary Argent-Katwala as Its Clinical Trial Manager
Calgary, Alberta--(Newsfile Corp. - June 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Mary Argent-Katwala to the position of Manager, Clinical Trials.Dr. Argent-Katwala earned her PhD in molecular biology from the Institute of Cancer Research, University of London, UK and her MA (Hons.), Biological Sciences at Newnham College, University of Cambridge, UK. Previously, Dr. Argent-Katwala was Director, Diagnosis & Clinical Care at the ...
- Newsfile
Hemostemix Announces Injunction Hearing Against Aspire Health Science, LLC
Calgary, Alberta--(Newsfile Corp. - June 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that it has retained DLA Piper, a global law firm, and filed for an injunction against Aspire Health Science, LLC, for the return of the Company's property. A hearing for the injunction is set for June 18, 2020 at 10:00 MDT before the Court of Queen's Bench, Alberta. Equally, the Company ...
- Newsfile
Hemostemix Announces Annual Special Meeting Results
Calgary, Alberta--(Newsfile Corp. - May 7, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces the Company completed its Annual Special Meeting of Shareholders on May 6, 2020. All motions put forward by management were approved by Shareholders, including the consolidation of the common shares on a one (1) new share for each 20 shares issued. The vote results are detailed in the attached table.Vote DetailsResolutionVote typeVotedVoted (%)O/S (%)Number of ...
- Newsfile
Hemostemix Announces Closing of Private Placement
Calgary, Alberta--(Newsfile Corp. - May 7, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") for gross proceeds of $1,291,500 (the "Offering"). The Offering consisted of the issuance of an aggregate of 129,150,000 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one ...
- Newsfile
Hemostemix Announces the Appointment of David Tsubouchi to its Board of Advisors
Calgary, Alberta--(Newsfile Corp. - April 30, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of David H. Tsubouchi, B.A., J.D., LL.D., D.S.Litt., C.Dir. to its Board of Advisors.David Tsubouchi is the first Japanese Canadian to be elected to any provincial legislature in Canada and to be appointed as a Cabinet Minister. He has served as the Minister of Consumer and Commercial Relations, Solicitor ...
- Newsfile
Hemostemix Announces Private Placement and Debt Settlement Update
Calgary, Alberta--(Newsfile Corp. - April 29, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that, subject to TSX Venture Exchange ("TSXV") approval, its non-brokered private placement will be increased from $450,000 to $1,223,200 of units (the "Units") at $0.01 per Unit (the "Offering"), and the settlement ("Debt Settlement") of trade payables will amount up to $358,514 at $0.01 per common share.Each Unit of the ...
- Newsfile
Hemostemix Announces the Appointment of Timothy Chang to Board of Advisors
Calgary, Alberta--(Newsfile Corp. - April 21, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Timothy C. Chang to its Board of Advisors. Mr. Chang is currently a Private Investor and an investment committee member of an Asian-based hedge fund with average total AUM of approximately US$1 billion. He has also been a consultant to Newport Healthcare Advisors and to SSG ...
- Newsfile
Hemostemix Announces the Appointments of Loran Swanberg and Christina Wu, CPA, CGA
Calgary, Alberta--(Newsfile Corp. - April 9, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Mr. Loran Swanberg to its Board of Directors. Mr. Swanberg is a successful businessman who increased his ownership of the Company from 0.8% in 2019 to 7.8% in 2020. In combination with Mssrs. Lacey, Hershman and Smeenk, the board now owns 21% of the Company's shares.Mr. Swanberg has been ...
- Newsfile
Hemostemix Appoints the Honourable Sheila Copps, OC, PC, to Board of Advisors and Ratifies Thomas Smeenk as Chief Executive Officer
Calgary, Alberta--(Newsfile Corp. - April 7, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of the Honorable Sheila Copps, OC, PC, to its Board of Advisors. Sheila was the Deputy Prime Minister of Canada, Minister of Environment, Minister of Heritage and a senior member of the federal cabinet for 10 years. From her work on diversity and inclusion, to protection of the environment, ...
- Newsfile
Hemostemix Announces Closing of Second Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - March 26, 2020) - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV: HEM) (OTC: HMTXF) announces it has closed the second tranche of its previously announced non-brokered private placement of units ("Units") for gross proceeds of up to $3,000,000 (the "Offering"). The second tranche of the Offering consisted of the issuance of an aggregate of 17,750,000 Units at a price of $0.01 per Unit for gross proceeds of $177,500. Each ...
- Newsfile
Hemostemix Announces Peter Lacey as Chairman of the Board of Directors
Calgary, Alberta--(Newsfile Corp. - March 19, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the election of Mr. Peter Lacey, ICD.D as Chairman of its Board of Directors. Peter Lacey is currently the Chairman of Cervus Equipment Corporation (CERV.TO), a company he and his partners started in 1999 and built from five John Deere dealerships into a company that owns 63 dealerships selling six brands ...
- Newsfile
Hemostemix Announces Dr. York Hsiang Joins Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - March 16, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of York N. Hsiang, MB. ChB, MHSc, FRCSC, Professor of Vascular Surgery at the University of British Columbia, and Consultant Surgeon at the Vancouver General Hospital, to its Scientific Advisory Board ("SAB").Born in Taiwan, educated in the United States, New Zealand, and Canada, Dr. Hsiang has diverse interests in vascular ...
- Newsfile
Hemostemix Announces Corporate Update
Calgary, Alberta--(Newsfile Corp. - March 10, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has paid $2,330,633.84 to counsel for J.M. Wood Investments Ltd,("JM Wood") in full satisfaction of the Court of Queen's Bench of Alberta Order dated February 28, 2020. JM Wood's application for the appointment of a receiver is now dismissed. Pursuant to the Order, the Company paid into trust with ...
- Newsfile
Hemostemix Announces Closing of First Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - March 5, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed the initial tranche of its previously announced non-brokered private placement of units ("Units") for gross proceeds of up to $3,000,000 (the "Offering"). The first tranche of the Offering consisted of the issuance of an aggregate of 254,620,442 Units at a price of $0.01 per Unit for gross proceeds of $2,546,204.42. ...
- CNW Group
IIROC Trading Resumption - HEM
VANCOUVER , March 2, 2020 /CNW/ - Trading resumes in: Company: Hemostemix Inc. TSX-Venture Symbol: HEM (All Issues) Resumption (ET): 9:30 AM IIROC can make a decision to impose a temporary suspension ...
- GlobeNewswire
Hemostemix Announces Financing Update and Secured Convertible Debenture Financing of Up to $2,000,000
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to announce that it is proceeding with its non-brokered private placement of units, as announced January 2, 2020 (the “Unit Offering”). In addition, the Company announces it is also proceeding with a non-brokered private placement of up to a maximum of $2,000,000 principal amount of secured convertible debentures (the “Debenture Offering”). Each debenture will consist of $1,000 principal amount of secured, non-transferable, convertible, redeemable debentures (the “Debentures”).
- GlobeNewswire
Hemostemix Provides Corporate Update and Clarification
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) provides the following corporate update and clarification of previous disclosure. The Company hereby retracts disclosure made by the Company in its January 2020 corporate presentations circulated by the Company as these presentations included several incorrect statements with respect to the number of patients treated, and the Company’s CLI clinical trial size.
- GlobeNewswire
Hemostemix Announces Private Placement
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTC: HMTXF), announces the Company will proceed with a non-brokered private placement of up to 300,000,000 units (the “Units”) at $0.01 per Unit for gross proceeds of up to $3,000,000 (the “Offering”). Each Unit is comprised of one common share of the Company (each a “Share”) and one share purchase warrant (each a “Warrant”). Each Warrant will entitle the holder to acquire one additional Share in the capital of the Company at a price of $0.05 per Warrant, for a period of one year from the date the Units are issued.
